ADAR1 Capital Management »

Context Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Context Therapeutics (CNTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Context Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Context Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Context Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $284k 206k 1.38

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Context Therapeutics

Deep Track Capital
Nextech Invest
Avidity Partners Management
Dr. Jeffrey R. Jay, M.D.
Blue Owl Capital Holdings
Vanguard Group
Blackstone Group
Nantahala Capital Management
Franklin Resources
Alyeska Investment Group
Woodline Partners
Sio Capital Management
Affinity Asset Advisors
BlackRock
BlackRock

View all funds holding Context Therapeutics